No Data
No Data
Anebulo Pharmaceuticals Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 EPS Results.
Anebulo Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Benchmark Co. Maintains Anebulo Pharmaceuticals(ANEB.US) With Buy Rating, Maintains Target Price $8
Express News | Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals | 10-K: FY2024 Annual Report
No Data
No Data